Introduction

Mixed Connective Tissue Disease (MCTD) is a rare and autoimmune disease that is also known as overlap disease, due to the symptoms of MCTD overlapping with many other disorders such as lupus, sclerosis and polymyositis/dermatomyositis and rheumatoid arthritis.¹ Although people of all ages can develop MCTD, including children, it is most common in females aged 20 to 30 years old.² 

Although diagnosing MCTD early is difficult, it is crucial to avoid complications that may be irreversible. In this article, we will cover the pathophysiology and immune basis of MCTD, its paediatric versus adult presentation, tailored treatments, outcomes, and emerging research.

Pathophysiology & immunology of MCTD

The role of connective tissues in the body is to support and connect organs. When connective tissues become inflamed, it can lead to damage to their protein components and adversely affect surrounding bodily structures.3 This is known as a connective tissue disorder. There are many different diseases that fall under the category of connective tissue disease. A type of connective tissue disease is are autoimmune disorders that occur when the body attacks itself rather than protecting it. Autoimmune diseases are chronic conditions, and there are over 100 different autoimmune diseases.⁴ 

One of the defining features of MCTD is a high quantity of anti-RNP antibodies found in the blood tests of patients. A recent study showed that over 95% of patients with MCTD had high quantities of the anti-RNP antibody found in their blood.⁵ The Anti-RNP antibody targets nuclear proteins involved in RNA processing and is highly specific for MCTD (rare in isolation in other autoimmune diseases) and is additionally linked to immune complex formation, inflammation, and tissue damage. 

While the exact cause of MCTD remains unknown, both genetic susceptibility (such as HLA-DR4) and environmental triggers (such as viral infections) are believed to be contributors. In children, the immune system is still undergoing development, which may explain systemic inflammation, sensitivity to treatment measures (particularly immunosuppressants) and different disease progression compared to adults.

Clinical presentation in children vs adults

MCTD can present differently in children as compared to adults. In all ages, common symptoms are: 

• Fatigue
• Joint pain 
• Raynaud’s phenomenon 
• Muscle weakness 
• Rash

In children, patients are more likely to present with severe Raynaud’s phenomenon, where blood stops flowing to the fingers and toes, causing them to turn white.⁶ In addition, children may also have the symptoms of more pronounced myositis, causing severe muscle weakness and pain, pulmonary involvement leading to the risk of pulmonary hypertension and delayed growth or puberty in some cases.⁷ 

In contrast, adult patients are more likely to present with more joint-focused symptoms that show a gradual onset. Additionally, vascular complications may be more advanced in adults. During a MCTD flare-up, children may feel severe pain in their muscles and/or joints, similar to patients who have rheumatoid arthritis. Cold or stress may cause fingers, hands and toes to turn numb and give off a tingling sensation. Children often develop symptoms that affect the whole body sooner than adults do, so they need to be watched and monitored more closely.

Treatment approaches in children

Whilst there is no current cure for MCTD, a mixture of medicines can be prescribed to effectively manage the symptoms. Corticosteroids, also known as steroids, are anti-inflammatory medicines that help reduce inflammation in the body and relieve symptoms of pain in order to calm down the immune system.⁸ 

Immunosuppressants can also be taken to weaken the immune system.⁹ Initially, the immunosuppressants may not display immediate results and should be taken for a few weeks to effectively work. Hydroxychloroquine may also be prescribed to reduce swelling and prevent flare-ups in the body during MCTD.¹⁰ 

As the symptoms of Raynaud phenomenon are more severe in children, calcium channel blockers may be prescribed to manage this.¹¹ They work by reducing blood pressure and allowing the blood vessels to open and relax. In addition, steroid-sparing agents such as methotrexate or azathioprine may be prescribed to slow down the immune system of children, and are commonly used to treat anti-inflammatory conditions such as MCTD. 

Due to the developing bodies and immune systems of children, the treatment approaches for children require special consideration. Although the medicines discussed previously are used in adults, paediatric cases often present atypically and may develop severe side effects as a result of treatment. 

One of the biggest concerns when dealing with treatment for MCTD in children is the prolonged use of corticosteroids, as this may lead to growth suppression, delayed puberty, bone density loss, and increased risk of infections. In order to combat this, many doctors may prescribe steroid-sparing agents, like methotrexate or azathioprine, earlier on in the treatment stages for MCTD as compared to adults. Additionally, the dosage for medications must be carefully adjusted based on the child’s weight and age, leading to complexities in treatment planning.

Children with MCTD may also present with more severe systemic involvement, including lung or cardiac complications. Hence, to avoid such complications, regular monitoring is essential. Some ways to monitor MCTD are pulmonary function tests to screen for pulmonary hypertension, echocardiograms to assess heart health, blood work to monitor liver, kidney, and bone marrow function and bone density scans in long-term steroid users.

Treatment response and long-term outcomes 

Treatment response in children with MCTD is generally positive, given that the diagnosis is made early and immune-targeting therapy is given early. In general, many children respond well to treatments such as corticosteroids and methotrexate, with noticeable reductions in inflammation, pain, and fatigue over weeks or months. However, because MCTD is a chronic relapsing autoimmune disease, flare-ups are common, especially during periods of rapid growth and puberty. 

Depending on the organs involved, variable outcomes may be experienced in children. Paediatric patients with major lung, heart, or kidney problems often face more serious long-term health issues. Conditions like pulmonary hypertension and interstitial lung disease are especially risky as they can cause lasting damage if not caught early. That said, many children do well over time, especially when they’re regularly supported by a team of healthcare professionals. With steady care, long stretches of stability or even remission are often possible.

Current research and future directions

Although the standard treatments for MCTD in children mentioned previously often lead to improvement of MCTD symptoms, there is ongoing research to optimise therapies and predict flare-ups. This can essentially personalise care for children with MCTD. 

One area of research involves biological therapies, such as rituximab (anti-CD20 monoclonal antibody) and belimumab (anti-BAFF), which could be given to children who do not respond well to traditional immunosuppressants. Rituximab and belimumab aim to target the autoimmune system, whilst reducing long-term effects in children.

Biomarkers are also being studied, such as certain cytokine profiles and anti-RNP antibody levels, to improve early diagnosis and predict disease activity or relapse probability. Advances in genetic and epigenetic research are helping identify susceptibility factors, which could one day support screening or preventative strategies in high-risk children.

Conclusion

Mixed Connective Tissue Disease (MCTD) in children is a complex, rare autoimmune disorder that presents overlapping features of several connective tissue diseases. Paediatric patients often exhibit more widespread and systemic symptoms compared to adults, requiring early diagnosis and a carefully tailored treatment approach. 

While traditional immunosuppressive therapies are generally effective, children face unique challenges such as growth suppression, medication side effects, and treatment adherence, particularly during adolescence. Advances in biologic therapies, biomarker research, and personalised medicine are opening new possibilities for safer and more effective long-term management. Ultimately, managing paediatric MCTD requires a multidisciplinary, child-centred approach that addresses not only physical health, but also emotional and developmental needs.

Frequently asked questions (FAQs)

Q1: Is MCTD curable in children?

A: MCTD is not curable, but with early and consistent treatment, most children can achieve long periods of remission and lead full lives.

Q2: How is MCTD different in children compared to adults?

A: Children often experience more systemic symptoms (like muscle inflammation and lung involvement) earlier and are more sensitive to long-term medication side effects.

Q3: What tests are used to diagnose MCTD?

A: Diagnosis relies on clinical symptoms and blood tests showing high levels of anti-U1 RNP antibodies, along with ruling out other autoimmune diseases.

Q4: Why is steroid use more carefully managed in children?

A: Long-term steroid use in children can impair growth, delay puberty, and affect bone health, so alternative immunosuppressants are often introduced early.

Q5: What are the future treatments for MCTD?

A: Current research is exploring biologics like rituximab and belimumab, along with biomarkers to better predict flares and personalise treatment.